About Killer cell immunoglobulin-like receptor 3DL1
Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1) is a protein
from Homo sapiens identified by UniProt accession
P43629, 444 residues long.
MolForge cross-references it against 0 known binders and
202 disease associations.
Target properties
| Protein name | Killer cell immunoglobulin-like receptor 3DL1 |
| UniProt accession | P43629 |
| Gene | KIR3DL1 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (202)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.40
- pancreatic adenocarcinoma · score 0.19
- 3-hydroxypropylmercapturic acid measurement · score 0.14
- keratoconus · score 0.14
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- hepatocellular carcinoma · score 0.10
- neoplasm · score 0.10
- COVID-19 · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P43629-F1 | alphafold | PREDICTED | 75.61 | — |
Amino-acid sequence (444 residues)
MSLMVVSMAC VGLFLVQRAG PHMGGQDKPF LSAWPSAVVP RGGHVTLRCH YRHRFNNFML YKEDRIHIPI FHGRIFQESF NMSPVTTAHA GNYTCRGSHP HSPTGWSAPS NPVVIMVTGN HRKPSLLAHP GPLVKSGERV ILQCWSDIMF EHFFLHKEGI SKDPSRLVGQ IHDGVSKANF SIGPMMLALA GTYRCYGSVT HTPYQLSAPS DPLDIVVTGP YEKPSLSAQP GPKVQAGESV TLSCSSRSSY DMYHLSREGG AHERRLPAVR KVNRTFQADF PLGPATHGGT YRCFGSFRHS PYEWSDPSDP LLVSVTGNPS SSWPSPTEPS SKSGNPRHLH ILIGTSVVII LFILLLFFLL HLWCSNKKNA AVMDQEPAGN RTANSEDSDE QDPEEVTYAQ LDHCVFTQRK ITRPSQRPKT PPTDTILYTE LPNAKPRSKV VSCP
Explore Killer cell immunoglobulin-like receptor 3DL1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets